Literature DB >> 6629652

Electrocochleography and brainstem potentials in the diagnosis of the deaf child.

E Arslan, S Prosser, G Conti, S Michelini.   

Abstract

The deaf child must receive sound amplification before he reaches the age of two years. At this age the hearing threshold is best measured objectively by electrocochleography (ECochG) and auditory brainstem response (ABR) audiometry. When used correctly, both methods allow an exact threshold estimation which is informative enough for adequate hearing aid prescription. Both methods have advantages and disadvantages when used in children. The advantages of ECochG are: (a) a more exact threshold estimation and (b) strictly monaural evaluation. The advantages of ABR are: (a) ease of performance; it is not invasive and does not require general anaesthesia and (b) allows for exploration of higher levels in the auditory pathway up to the midbrain. We believe that ECochG and ABR are compatible and complementary in the diagnosis of childhood deafness. ABR could be used in first instance, while ECochG could be reserved for doubtful cases and for those who cannot be adequately sedated. Extra-audiological factors such as the availability of anaesthetists and varying hospital facilities, play a further role in determining the choice of electric response technique.

Entities:  

Mesh:

Year:  1983        PMID: 6629652     DOI: 10.1016/s0165-5876(83)80037-8

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  2 in total

1.  Cochlear Microphonic and Summating Potential Responses from Click-Evoked Auditory Brain Stem Responses in High-Risk and Normal Infants.

Authors:  Lisa L Hunter; Chelsea M Blankenship; Rebekah G Gunter; Douglas H Keefe; M Patrick Feeney; David K Brown; Kelly Baroch
Journal:  J Am Acad Audiol       Date:  2018-05       Impact factor: 1.664

2.  Auditory brainstem responses to clicks and tone bursts in C57 BL/6J mice.

Authors:  P Scimemi; R Santarelli; A Selmo; F Mammano
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-08       Impact factor: 2.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.